Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.

"Disclosure statement : M.K. reports grants and personal fees from Boehringer Ingelheim and Roche, and personal fees from Galapagos. F.B. reports grants and personal fees from Boehringer Ingelheim, Roche, Galapagos and Savara Pharma. N.B. reports personal fees from Actelion, Boehringer Ingelheim, Roche, Pfizer, MSD and AbbVie, and grants and personal fees from Novartis and SOBI. J.H. reports grants and personal fees from AbbVie, Boehringer Ingelheim, Roche/Chugai, Janssen, Novartis, Pfizer and UCB. C.G. reports fees from Novartis, Boehringer Ingelheim and Amgen. C.P. reports personal fees from Boehringer Ingelheim, Pfizer and Takeda, grants and personal fees from Actelion and Novartis, and grants from Corbus and Amgen. M.S. reports grants and personal fees from Roche/Chugai, Hexal/Sandoz, Janssen and BMS, and personal fees from AbbVie, Novartis, UCB, Boehringer Ingelheim and Gilead. GZ reports a lecture for Janssen. P.K. reports personal fees and non-financial support from AbbVie, Chugai, Novartis and Pfizer unrelated to the present manuscript, and personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline and Janssen-Cilag unrelated to the present manuscript. A.J. reports personal fees from Boehringer Ingelheim and AbbVie. J.E. reports personal fees for advisory board participation from Boehringer Ingelheim, and for lectures from Actelion, Janssen and Boehringer Ingelheim. N.H. reports personal fees for advisory participation from Boehringer Ingelheim, and lectures from Actelion, Boehringer Ingelheim and Roche. G.R., U.M.-L., E.S., I.K., L.S., M.W., I.J., C.S., G.K., A.R., T.S., A.K., K.K., H.M.-L. and P.M. have declared no conflicts of interest. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations."

"Funding Analysis of ILD-related data was supported by Boehringer Ingelheim International GmbH. No author received payment for the development of this manuscript. Writing support was provided by Chester Trinick and Helen Keyworth of Nucleus Global, which was contracted and funded by Boehringer Ingelheim. Disclosure statement: M.K. reports grants and personal fees from Boehringer Ingelheim and Roche, and personal fees from Galapagos. F.B. reports grants and personal fees from Boehringer Ingelheim, Roche, Galapagos and Savara Pharma. N.B. reports personal fees from Actelion, Boehringer Ingelheim, Roche, Pfizer, MSD and AbbVie, and grants and personal fees from Novartis and SOBI. J.H. reports grants and personal fees from AbbVie, Boehringer Ingelheim, Roche/Chugai, Janssen, Novartis, Pfizer and UCB. C.G. reports fees from Novartis, Boehringer Ingelheim and Amgen. C.P. reports personal fees from Boehringer Ingelheim, Pfizer and Takeda, grants and personal fees from Actelion and Novartis, and grants from Corbus and Amgen. M.S. reports grants and personal fees from Roche/Chugai, Hexal/Sandoz, Janssen and BMS, and personal fees from AbbVie, Novartis, UCB, Boehringer Ingelheim and Gilead. GZ reports a lecture for Janssen. P.K. reports personal fees and non-financial support from AbbVie, Chugai, Novartis and Pfizer unrelated to the present manuscript, and personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline and Janssen-Cilag unrelated to the present manuscript. A.J. reports personal fees from Boehringer Ingelheim and AbbVie. J.E. reports personal fees for advisory board participation from Boehringer Ingelheim, and for lectures from Actelion, Janssen and Boehringer Ingelheim. N.H. reports personal fees for advisory participation from Boehringer Ingelheim, and lectures from Actelion, Boehringer Ingelheim and Roche. G.R., U.M.-L., E.S., I.K., L.S., M.W., I.J., C.S., G.K., A.R., T.S., A.K., K.K., H.M.-L. and P.M. have declared no conflicts of interest. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations."